The goal of this study is to understand the role that our genes, gut microbiome, and environmental factors play in the development of autism. We hope to identify potential biomarkers (in the blood, stool, urine and saliva) predictive of autism development and ultimately predict, prevent and treat ASD symptoms and GI comorbidities. We are currently recruiting Infants 0-6 months of age who have a sibling diagnosed with ASD are eligible to participate. The study involves periodic collection of blood, stool, urine and saliva samples over a 3-year period as well as periodic questionnaires regarding child’s social, medical and dietary history. Autism evaluations will also be administered every 6 months starting at 1 year of age to monitor child’s development.
Children who develop autism while enrolled will be eligible for the GEMMA interventional study: This study will use the identified biomarkers to implement personalized prevention and treatment of ASD and ASD-related symptoms. This information will provide a rational basis for early autism diagnosis and/or may help to formulate a specific therapeutic intervention to restore gut microflora from dysbiosis to a state of symbiosis. This will also provide further insights in investigating the sex bias related to the development of autism.